Amendment: SEC Form SC 13G/A filed by INmune Bio Inc.

$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $INMB alert in real time by email
SC 13G/A 1 inmunebioinc-xencorsc13g20.htm SC 13G/A Document

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
INmune Bio, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
45782T105
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





CUSIP No. 45782T105
 
  1   
  NAMES OF REPORTING PERSONS
 Xencor, Inc.
  2 
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)  ☐        (b)  ☒
 
  3 
  SEC USE ONLY
 
  4 
  CITIZENSHIP OR PLACE OF ORGANIZATION
 
  Delaware
NUMBER OF
SHARES
 BENEFICIALLY 
OWNED BY
EACH
REPORTING
PERSON
WITH:
  5    
  SOLE VOTING POWER
 
  1,885,533
  6  
  SHARED VOTING POWER
 
  0
  7  
  SOLE DISPOSITIVE POWER
 
  1,885,533
  8  
  SHARED DISPOSITIVE POWER
 
  0
  9   
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
  1,885,533
10 
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
  
11 
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
  9.6%(1)
12 
  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
  CO

(1)     This percentage is calculated based upon 19,706,732 shares of the Issuer’s Common Stock outstanding as set forth in the Issuer’s Form 10-Q for the second quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024.


Item 1(a).    Name of Issuer:
INmune Bio, Inc.



Item 1(b).    Address of Issuer’s Principal Executive Offices:
225 NE Mizner Blvd., Suite 640,
Boca Raton, FL 33432
Item 2(a).    Name of Person Filing:
Xencor, Inc.
(the “Reporting Person”)
Item 2(b).    Address of Principal Business Office or, if none, Residence:

The address of the principal business office of the Reporting Person is:
465 N. Halstead St. Suite 200
Pasadena, California 91107
Item 2(c).    Citizenship:
The Reporting Person is a corporation organized under the laws of the State of Delaware.
Item 2(d).    Title of Class of Securities:
Common Stock, par value $0.001 per share (“Common Stock”)
Item 2(e).    CUSIP Number:
45782T105
Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable
Item 4.    Ownership

The Reporting Person directly holds 1,885,533 shares of Common Stock. The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G/A.
Item 5.    Ownership of 5 Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
Item 6.    Ownership of More than 5 Percent on Behalf of Another Person:
Not applicable
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:
Not applicable
Item 8.    Identification and Classification of Members of the Group:
Not applicable
Item 9.    Notice of Dissolution of a Group:
Not applicable
Item 10.    Certifications:
Not applicable



SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: October 2, 2024
XENCOR, INC.

By:
/s/ Celia Eckert
Celia Eckert
General Counsel & Corporate Secretary


ATTENTION:
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)



Get the next $INMB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INMB

DatePrice TargetRatingAnalyst
1/28/2025$23.00Buy
Rodman & Renshaw
10/21/2024$20.00Buy
Alliance Global Partners
9/27/2024$18.00Outperform
Raymond James
8/22/2024$22.00Sector Outperform
Scotiabank
6/1/2023$16.00Outperform
Robert W. Baird
5/24/2022$14.00 → $7.00Buy → Neutral
B. Riley Securities
1/24/2022$32.00 → $20.00Buy
B. Riley Securities
7/7/2021$32.00 → $42.00Buy
Maxim Group
More analyst ratings

$INMB
Press Releases

Fastest customizable press release news feed in the world

See more
  • INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

    BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

    Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

    Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the "CaRe PC" trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort. The Scientific Review Committee (SRC) charter is to re

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$INMB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$INMB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$INMB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$INMB
SEC Filings

See more

$INMB
Leadership Updates

Live Leadership Updates

See more
  • INmune Bio Inc. to Join Russell 3000® Index

    Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

    DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$INMB
Financials

Live finance-specific insights

See more
  • INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

    BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

    Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

    BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$INMB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$INMB
Insider purchases explained

Analytical look into recent insider purchases

See more
  • Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care